[{"orgOrder":0,"company":"RS BioTherapeutics","sponsor":"Synthonics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"RSBT-001","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"RS BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"","sponsorNew":"RS BioTherapeutics \/ Synthonics","highestDevelopmentStatusID":"4","companyTruncated":"RS BioTherapeutics \/ Synthonics"},{"orgOrder":0,"company":"RS BioTherapeutics","sponsor":"Synthonics","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"RSBT-001","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"RS BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"","sponsorNew":"RS BioTherapeutics \/ Synthonics","highestDevelopmentStatusID":"4","companyTruncated":"RS BioTherapeutics \/ Synthonics"},{"orgOrder":0,"company":"RS BioTherapeutics","sponsor":"Synthonics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2022","type":"Financing","leadProduct":"Cannabidiolic Acid Complex","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"RS BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"","sponsorNew":"RS BioTherapeutics \/ Synthonics","highestDevelopmentStatusID":"4","companyTruncated":"RS BioTherapeutics \/ Synthonics"},{"orgOrder":0,"company":"RS BioTherapeutics","sponsor":"Recipharm AB","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2022","type":"Partnership","leadProduct":"RSBT-001","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"RS BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"","sponsorNew":"RS BioTherapeutics \/ Recipharm AB","highestDevelopmentStatusID":"4","companyTruncated":"RS BioTherapeutics \/ Recipharm AB"},{"orgOrder":0,"company":"RS BioTherapeutics","sponsor":"National Institute on Alcohol Abuse and Alcoholism","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Cannabidiolic Acid Complex","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"RS BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"","sponsorNew":"RS BioTherapeutics \/ National Institute on Alcohol Abuse and Alcoholism","highestDevelopmentStatusID":"4","companyTruncated":"RS BioTherapeutics \/ National Institute on Alcohol Abuse and Alcoholism"},{"orgOrder":0,"company":"RS BioTherapeutics","sponsor":"University of Colorado School of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"RSBT-001","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"RS BioTherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"RS BioTherapeutics \/ University of Colorado School of Medicine","highestDevelopmentStatusID":"14","companyTruncated":"RS BioTherapeutics \/ University of Colorado School of Medicine"}]

Find Clinical Drug Pipeline Developments & Deals by RS BioTherapeutics

Menu
Xls
Filters Filter
Ă—
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : The collaboration aims to advance the clinical development of RSBT-001, which is being evaluated in the early-stage clinical trial studies for the treatment of COPD and IPF.

                          Brand Name : RSBT-001

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          July 08, 2024

                          Lead Product(s) : RSBT-001

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Preclinical

                          Sponsor : University of Colorado School of Medicine

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Lead Product(s) : Cannabidiolic Acid Complex

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Study Phase : Preclinical

                          Sponsor : National Institute on Alcohol Abuse and Alcoholism

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          Details : The collaboration aims to assess the anti-inflammatory and anti-fibrotic potential of RS BioTherapeutics’ lead compound, RSBT-001, an investigational semi-synthetic cannabidiolic acid complex, in a preclinical pulmonary fibrosis model.

                          Brand Name : RSBT-001

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          August 29, 2023

                          Lead Product(s) : Cannabidiolic Acid Complex

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Preclinical

                          Sponsor : National Institute on Alcohol Abuse and Alcoholism

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          03

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : Product characterization is an important next step for RSBT-001 before filing an Investigational New Drug (IND) application with the FDA for the treatment of chronic obstructive pulmonary disease (COPD).

                          Brand Name : RSBT-001

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          November 14, 2022

                          Lead Product(s) : RSBT-001

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Recipharm AB

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          04

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : RSBT-001 is a patent-pending, nebulized, semi-synthetic, cannabidiolic acid complex in development to address exacerbation and prevent progression of both acute and chronic pulmonary inflammation related to respiratory diseases.

                          Brand Name : RSBT-001

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          September 26, 2022

                          Lead Product(s) : Cannabidiolic Acid Complex

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Synthonics

                          Deal Size : $3.0 million

                          Deal Type : Financing

                          blank

                          05

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : The data from the proof-of-concept trial clearly indicates that RSBT-001, is a patent-pending, nebulized, semi-synthetic, cannabidiolic acid (CBDa) reduces cytokine level, and that this cytokine reduction is appropriately transient.

                          Brand Name : RSBT-001

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          July 11, 2022

                          Lead Product(s) : RSBT-001

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Synthonics

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : Under the license agreement with Synthonics, Inc. for the exclusive, worldwide right for RS BioTherapeutic's lead compound, RSBT-001, as both an alternative and a complement to corticosteroids for the treatment of chronic obstructive pulmonary disease (C...

                          Brand Name : RSBT-001

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          May 23, 2022

                          Lead Product(s) : RSBT-001

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Synthonics

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank